Australia markets closed

GlaxoSmithKline plc (GLAXF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
19.27-0.17 (-0.90%)
At close: 3:57PM EDT
Show:
Balance sheet
Cash flow
Annual

Income statement

Currency in GBP. All numbers in thousands
Breakdown
ttm
31/12/2020
31/12/2019
31/12/2018
31/12/2017
Total revenue
32,895,000
34,099,000
33,754,000
30,821,000
30,186,000
Cost of revenue
11,090,000
11,704,000
11,863,000
10,241,000
10,342,000
Gross profit
21,805,000
22,395,000
21,891,000
20,580,000
19,844,000
Operating expenses
Research development
4,950,000
5,098,000
4,568,000
3,893,000
4,476,000
Selling general and administrative
10,900,000
11,456,000
11,402,000
9,915,000
9,672,000
Total operating expenses
17,077,000
16,171,000
15,599,000
13,516,000
13,783,000
Operating income or loss
4,728,000
6,224,000
6,292,000
7,064,000
6,061,000
Interest expense
791,000
856,000
885,000
771,000
736,000
Income before tax
5,480,000
6,968,000
6,221,000
4,800,000
3,525,000
Income tax expense
413,000
580,000
953,000
754,000
1,356,000
Income from continuing operations
5,067,000
6,388,000
5,268,000
4,046,000
2,169,000
Net income
4,389,000
5,749,000
4,645,000
3,623,000
1,532,000
Net income available to common shareholders
4,389,000
5,749,000
4,645,000
3,623,000
1,532,000
Basic EPS
-
1.16
0.94
0.74
0.31
Diluted EPS
-
1.14
0.93
0.73
0.31
Basic average shares
-
4,976,000
4,947,000
4,914,000
4,886,000
Diluted average shares
-
5,038,000
5,016,000
4,971,000
4,941,000
EBITDA
-
10,175,000
9,440,000
7,427,000
6,183,000